Lacipil

Looking for 103890-78-4 / Lacidipine API manufacturers, exporters & distributors?

PharmaCompass offers a list of Lacidipine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lacidipine manufacturer or Lacidipine supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lacidipine manufacturer or Lacidipine supplier.

PharmaCompass also assists you with knowing the Lacidipine API Price utilized in the formulation of products. Lacidipine API Price is not always fixed or binding as the Lacidipine Price is obtained through a variety of data sources. The Lacidipine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Lacidipine

Synonyms

103890-78-4, Lacipil, Motens, Gr-43659x, Trans lacidipine, Gr 43659x

Cas Number

103890-78-4

Unique Ingredient Identifier (UNII)

260080034N

About Lacidipine

Lacidipine is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity. Due to its long duration of action, lacidipine does not lead to reflex tachycardia. It displays specificity in the vascular smooth muscle, where it acts as an antihypertensive agent to dilate peripheral arterioles and reduce blood pressure. Compared to other dihydropyridine calcium antagonists, lacidipine exhibits a greater antioxidant activity which may confer potentially beneficial antiatherosclerotic effects. Lacidipine is a highly lipophilic molecule that interacts with the biological membranes. Through radiotracer analysis, it was determined that lacidipine displays a high membrane partition coefficient leading to accumulation of the drug in the membrane and slow rate of membrane washout. When visualized by small-angle X-ray diffraction with angstrom resolution to examine its location within the membranes, lacidipine was found deep within the membrane's hydrocarbon core. These results may explain the long clinical half-life of lacidipine. In randomised, well-controlled trials, administration of daily single-dose lacidipine ranging from 2-6 mg demonstrated comparable antihypertensive efficacy similar to that of other long-acting dihydropyridine calcium antagonists, thiazide diuretics, atenolol (a beta-blocker) and enalapril (an ACE inhibitor). It is available as once-daily oral tablets containing 2 or 4 mg of the active compound commonly marketed as Lacipil or Motens. It is not currently FDA-approved.

Lacipil Manufacturers

A Lacipil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lacipil, including repackagers and relabelers. The FDA regulates Lacipil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lacipil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Lacipil manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Lacipil Suppliers

A Lacipil supplier is an individual or a company that provides Lacipil active pharmaceutical ingredient (API) or Lacipil finished formulations upon request. The Lacipil suppliers may include Lacipil API manufacturers, exporters, distributors and traders.

click here to find a list of Lacipil suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Lacipil KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Lacipil Drug Master File in Korea (Lacipil KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Lacipil. The MFDS reviews the Lacipil KDMF as part of the drug registration process and uses the information provided in the Lacipil KDMF to evaluate the safety and efficacy of the drug.

After submitting a Lacipil KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Lacipil API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Lacipil suppliers with KDMF on PharmaCompass.

Lacipil Manufacturers | Traders | Suppliers

We have 2 companies offering Lacipil

Get in contact with the supplier of your choice:

LEBSA
GSK

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.

Lacipil

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

8 API Suppliers

1 USDMF

4 EU WC

2 KDMF

1 NDC API

5 Listed Suppliers

$ API Reference Price

INTERMEDIATES

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

43 FDF Dossiers

40 Europe

3 Listed Dossiers

GLOBAL SALES INFORMATION

40 Regulatory FDF Prices

MARKET PLACE

1 FDF Dossiers

REF. STANDARDS & IMPURITIES

1 Others

ANALYTICAL

1 BioAnalytical Methods

Filters

01

LEBSA

02

GSK

GSK